MedTrace Logo

Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer

NCT05372081 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-05-13

No results posted yet for this study

Summary

The purpose of this study is to provide high quality oncology services to patients with inoperable Non-Small Cell Lung Cancer (NSCLC) in Greece. These services will be based on 3 pillars:

1. Clinical: personalized treatment will be administered and its effectiveness and safety will be recorded and evaluated.
2. Molecular: the gene footprint of each patient at the beginning of his treatment, the molecular identity of his tumor will be analyzed and recorded based on analysis with modern Next Generation Sequencing (NGS) techniques.
3. Digital: Patients will have access to the digital platform where they will record the adverse reactions they will face during their treatment.

Conditions

  • Non-Small Cell Carcinoma of Lung, TNM Stage 4

Interventions

OTHER

Digital platform

Patients will be randomized (1:1) in the way they will receive or not any assistance from the digital platform.

Sponsors & Collaborators

  • Stavros Niarchos Foundation

    collaborator UNKNOWN

  • Care Across Ltd

    collaborator UNKNOWN

  • Hellenic Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Paris Kosmidis, MD · YGEIA Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-23
Primary Completion
2024-09-30
Completion
2025-03-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05372081 on ClinicalTrials.gov